Search - tctmd.com

Displaying 1 - 8 of 8

Sort: Relevancy | Date

Vutrisiran, an siRNA for ATTR-CM, Meets Primary Endpoint in HELIOS-B

News Daily News

Vutrisiran, an siRNA for ATTR-CM, Meets Primary Endpoint in HELIOS-B

Michael O'Riordan

June 24, 2024

ATTRibute-CM Top-Line Results Favorable for Acoramidis in Transthyretin Amyloidosis

News Daily News

ATTRibute-CM Top-Line Results Favorable for Acoramidis

July 17, 2023

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

News Features

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Michael O'Riordan

January 10, 2020

Tafamidis Approved for Treatment of Transthyretin Amyloid Cardiomyopathy

News Daily News

Tafamidis Approved for Treatment of Transthyretin Amyloid Cardiomyopathy

Michael O'Riordan

May 06, 2019

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

News Conference News AHA 2018

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

November 05, 2018

Tafamidis, a Transthyretin Stabilizer, Offers Hope for Rare Cardiomyopathy

News Conference News ESC 2018

Tafamidis, a Transthyretin Stabilizer, Offers Hope for Rare Cardiomyopathy

Michael O'Riordan

August 27, 2018

News Daily News

Drug for Rare Form of Cardiomyopathy Meets Primary Endpoint in Phase III Trial

March 30, 2018

News Industry News

Heart Metabolics Announces Initiation Of Phase 2b Study Of Perhexiline For Hypertrophic Cardiomyopathy

August 31, 2016

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.